Skip to main content
PROF
NASDAQ Industrial Applications And Services

Profound Medical Q2 Revenue Up 12%, Reiterates $25M Full-Year Guidance; First Employer Health Plans Cover TULSA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.94
Mkt Cap
$288.521M
52W Low
$3.76
52W High
$8.95
52W Position info
111% above low
Off High info
11% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PROF has more than doubled off its 52-week low of $3.76.

Summary

Profound Medical reported Q2 2026 revenue of $2.5 million, up 12% year-over-year, and reiterated full-year revenue guidance of $25 million. The company announced its first employer-owned health plans covering the TULSA Procedure, a record $7 million in quarterly purchase orders, and a $3.1 million shipment delay that will benefit Q3.


Key Events · Earnings and Guidance · PROF

  • Q2 Revenue Up 12%, Net Loss Improves 39%

    Revenue of $2.5 million, up 12% year-over-year, with gross margin expanding to 78%. Net loss improved 39% to $9.5 million, driven by a 16% decline in operating expenses.

  • Record $7M in Purchase Orders, $3.1M Shipment Delay

    New purchase orders exceeded $7.0 million in Q2, a quarterly record. Approximately $3.1 million in TULSA shipments were delayed to early Q3 due to a temporary logistics issue, which would have boosted Q2 revenue to ~$5.6 million (153% growth).

  • First Employer Health Plans Cover TULSA Procedure

    Johns Hopkins Employee Health Plan and Prime Healthcare Employee Health Plan, covering over 105,000 employees, medical staff, and family members, became the first employer-owned health plans to list the TULSA Procedure as a covered service.

  • Full-Year 2026 Revenue Guidance Reiterated at $25M

    Management reiterated its full-year 2026 revenue guidance of approximately $25.0 million, representing 56% growth over 2025, with gross margin expected to remain above 70%.


Analysis · PROF · Industrial Applications And Services

Profound Medical delivered a solid Q2 with revenue up 12% to $2.5 million, but the real story is the commercial momentum: record purchase orders of over $7 million, a $3.1 million shipment delay that will boost Q3, and the first employer-owned health plans now covering the TULSA Procedure. The company reiterated its $25 million full-year revenue target, implying 56% growth, and operating leverage is kicking in — gross margin hit 78% and operating expenses fell 16%. With $38.3 million in cash and a $70 million qualified pipeline, the business is gaining traction, though the net loss of $9.5 million still burns cash. The new employer coverage is a key reimbursement milestone that could accelerate adoption.

At the time of this filing, PROF was trading at $7.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $288.5M. The 52-week trading range was $3.76 to $8.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PROF - Latest Insights

PROF
Aug 06, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.94
Real-time Price: $7.94 info
Change: $0 (0%) info
Market Cap: $288.521M info
PROF
Jul 24, 2026, 11:58 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $7.94 info
Change: +$0.940 (+13%) info
Market Cap: $288.521M info
PROF
May 15, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $7.94 info
Change: +$0.970 (+14%) info
Market Cap: $288.521M info
PROF
May 14, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.20
Real-time Price: $7.94 info
Change: +$0.740 (+10%) info
Market Cap: $288.521M info
PROF
May 12, 2026, 5:05 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $7.14
Real-time Price: $7.94 info
Change: +$0.800 (+11%) info
Market Cap: $288.521M info